Literature DB >> 21740947

Barriers of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies.

Shayesta Dhalla1, Gary Poole.   

Abstract

Barriers to participation in an HIV vaccine trial have been examined in many HIV vaccine preparedness studies (VPS). These barriers can be understood in terms of the locus of the barrier (personal vs. social) and the nature of the barrier (risk vs. cost). Another type of barrier is perceived misconceptions. In this systematic review, we categorize barriers, and compare these barriers between the Organization for Economic Co-operation and Development (OECD) countries and the non-OECD countries. In the OECD countries, we retrieved 25 studies reporting personal risks (PR), 9 studies reporting social risks (SR), 10 studies reporting personal costs (PC), and 16 studies reporting misconceptions. In the non-OECD countries, we retrieved 27 studies reporting PR, 19 studies reporting SR, 18 studies reporting PC, 1 study reporting social costs (SC), and 13 studies reporting misconceptions. Important PR were "adverse effects" and "vaccine-induced seropositivity", "distrust of institutions", and "temptation to have unsafe sex" in men who have sex with men (MSM). "Discrimination" was a common SR. "Time commitment" was an important PC, and "family commitments" were a SC in one non-OECD country. "HIV infection from the vaccine" was a common misconception. Both the OECD and the non-OECD countries have similar barriers, and people's decisions to participate in a clinical trial involve multiple barriers. However, these barriers apply to hypothetical HIV vaccine trials, and barriers for actual vaccine trials need further assessment.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21740947     DOI: 10.1016/j.vaccine.2011.06.055

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

Review 1.  Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical prevention.

Authors:  Shayesta Dhalla; Gary Poole
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Recruitment of urban US women at risk for HIV infection and willingness to participate in future HIV vaccine trials.

Authors:  Barbara Metch; Ian Frank; Richard Novak; Edith Swann; David Metzger; Cecilia Morgan; Debbie Lucy; Debora Dunbar; Parrie Graham; Tamra Madenwald; Gina Escamilia; Beryl Koblin
Journal:  AIDS Behav       Date:  2013-02

3.  Legal and ethical values in the resolution of research-related disputes: how can IRBS respond to participant complaints?

Authors:  Kristen Underhill
Journal:  J Empir Res Hum Res Ethics       Date:  2014-02       Impact factor: 1.742

4.  Understanding Willingness to Participate in HIV Biomedical Research: A Mixed Methods Investigation.

Authors:  Ji-Young Lee; Sara M St George; Torsten B Neilands; Allan Rodriguez; Daniel J Feaster; Adam W Carrico
Journal:  AIDS Behav       Date:  2021-06-15

5.  Patient recruitment into a multicenter randomized clinical trial for kidney disease: report of the focal segmental glomerulosclerosis clinical trial (FSGS CT).

Authors:  Maria Ferris; Victoria Norwood; Milena Radeva; Jennifer J Gassman; Amira Al-Uzri; David Askenazi; Tej Matoo; Maury Pinsk; Amita Sharma; William Smoyer; Jenna Stults; Shefali Vyas; Robert Weiss; Debbie Gipson; Frederick Kaskel; Aaron Friedman; Marva Moxey-Mims; Howard Trachtman
Journal:  Clin Transl Sci       Date:  2012-10-30       Impact factor: 4.689

6.  Representation of Latinos and Blacks in screening for and enrollment into preventive HIV vaccine trials in New York City.

Authors:  Tanya M Ellman; Kellie Hawkins; Jorge Benitez; Ramon Negron; Steven Chang; Steven Palmer; Verna Robertson; Mary Ann Chiasson; Magdalena E Sobieszczyk
Journal:  Vaccine       Date:  2015-10-11       Impact factor: 3.641

7.  Enhanced retention strategies and willingness to participate among hard-to-reach female sex workers in Barcelona for HIV prevention and vaccine trials.

Authors:  M Florencia Etcheverry; Jennifer L Evans; Emilia Sanchez; Eva Mendez-Arancibia; Mercé Meroño; José M Gatell; Kimberly Page; Joan Joseph
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

8.  Implementing strategies in consumer and community engagement in health care: results of a large-scale, scoping meta-review.

Authors:  Pooria Sarrami-Foroushani; Joanne Travaglia; Deborah Debono; Jeffrey Braithwaite
Journal:  BMC Health Serv Res       Date:  2014-09-18       Impact factor: 2.655

9.  Willingness to participate in HIV vaccine trials among men who have sex with men in Chennai and Mumbai, India: a social ecological approach.

Authors:  Venkatesan Chakrapani; Peter A Newman; Neeti Singhal; Jhalak Jerajani; Murali Shunmugam
Journal:  PLoS One       Date:  2012-12-04       Impact factor: 3.240

10.  Barriers and facilitators of HIV vaccine and prevention study participation among Young Black MSM and transwomen in New York City.

Authors:  Sharise Richardson; Pich Seekaew; Beryl Koblin; Tasha Vazquez; Vijay Nandi; Hong-Van Tieu
Journal:  PLoS One       Date:  2017-07-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.